2026 industry trends in anti-obesity drug development
Read about how anti-obesity therapeutics in 2026 reflect a clear transition beyond first-generation incretin-based therapies.
Supporting next-generation Alzheimer’s disease research with quantitative whole-brain imaging
With whole-brain spatial imaging, teams can move from selected sections to atlas-aligned, brain-wide endpoints that support more confident decisions in neurodegenerative disease research.
Understanding the blood-brain barrier: Function, structure, and role in CNS drug delivery
Explore how Gubra supports preclinical BBB studies that integrate CNS drug delivery with spatial characterization of disease biology.
Quantifying neurodegenerative disease with 3D Imaging: A new standard in preclinical CNS research
The challenge of accurately quantifying neurodegeneration in preclinical models Neurodegenerative disease is a spatially distributed, circuit-level process rather than a focal pathology. In Alzheimer’s disease (AD) mouse models, amyloid-β (Aβ) pathology and neuroinflammation extend across cortical and hippocampal regions. In…
How to choose the right model for atherosclerosis studies
The efficacy of an anti-atherosclerotic compound is only as good as the method used to measure it. Explore the difference between the DIO-LDLR-KO mouse model and the DIO-AAV-PCSK9 mouse model.
What does c-Fos really measure? Interpreting neuronal activation in research
In this article, we dive deeper into c-Fos, its function, and how it can be used in research.
How to utilize whole brain imaging in preclinical obesity studies
Leverage Gubra’s expertise in both obesity and 3D imaging.
Understanding c-Fos and its applications in CNS research
What is c-Fos? c-Fos is an immediate-early gene that is activated in central nervous system (CNS) neurons upon exposure to neurotransmitters or activating stimulation. The c-Fos protein is a member of a transcription factor complex that will activate other genes to…